« Return to News | Drug Sponsors

UPM purchases Pfizer commercial manufacturing site

Monday, June 3, 2013 11:32 AM

UPM Pharmaceuticals, a Baltimore, Md.-based drug development and contract manufacturer, will acquire the 500,000-square-foot commercial manufacturing facility Pfizer currently operates in Bristol, Tenn.

The acquisition of the Pfizer facility will provide UPM with large-scale commercial capabilities for manufacturing and packaging of solid oral dosage tablets and capsules, as well as semi-solid manufacturing of creams and ointments. The facility will also provide comprehensive tech transfer support, pilot plant scale-up capabilities and analytical and microbial testing, as well as dedicated suites for potent compounds.  UPM will continue to manufacture Pfizer's current portfolio of products within the facility for two years. The acquisition will allow UPM to offer a full range of development, testing and manufacturing capabilities to existing and new clients.

"With the new facility, UPM will now be able to offer clients a seamless transition from early-stage formulation development to commercialization along with all associated comprehensive lab support,” said UPM president James E. Gregory. “The new facility will give UPM the capability to annually produce 3.5 billion tablets and 680 million capsules.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.